ADOPTIVE IMMUNOTHERAPY (AI)
- Adoptive Transfer of IL-2-activated Natural Killer (NK) Cells
NOVEL DRUG DELIVERY FOR TUMOR TARGETING AND IMAGING
- Biologic Agents as Delivery Vehicles
- Cytokine-induced killer (CIK) Cells
- Nanotechnology
INTEGRATING MOLECULAR TARGETS AND BIOMARKERS
- Correlation of Apoptosis, p53, and Mitochondria
TARGETING THE TUMOR MICROENVIRONMENT
- Vaccines
- Prodrugs
- Peritumoral Acinar Tissue Imaging
IMAGING OF TUMORS
- Proteomic Mapping and Imaging
- Imaging of Signal Transduction Pathways
- Imaging of Tumors/Microenvironment
- Monitoring of Cyclooxygenase-2 (Cox-2) to Assess Tumor Progression
VECTORS
- Pancreatic Cancer-specific Vector
- Breast Cancer-specific Vector
- Endostatin Prodrug
- Viral-based Therapy for Multiple Myeloma
- Targeted adn Shielded Adenovirus Vectors
- Whole Cell Vaccines for Acute Myeloid Leukemia (AML)
- Replication-competent Retroviral (RCR) Vectors
LIST OF EXHIBITS
Exhibit 1 - Potential Treatment Implication(s) of Selected Related EGFr Pathway Mutations
Exhibit 2 - EGFr Family Member Expression Rates (%) in Human Malignancies
Exhibit 3 - Epidermal Growth Factor (EGF) Receptor (EGFr) in Malignancy
Exhibit 4 - HEr2/neu (Her-2/neu) in Malignancy
Exhibit 5 - ErbB3 in Malignancy
Exhibit 6 - ErbB4 in Malignancy
Exhibit 7 - Epidermal Growth Factor Receptor Variant III (EGFrvIII) in Malignancy
Exhibit 8 - Selected EGFr Family Small Molecule Tyrosine Kinase Inhibitors (TKI)
Exhibit 9 - Selected ErbB Receptor-Based Immunotherapies/Vaccine Approaches
